Feasibility IB Trial of Paclitaxel/Carboplatin + Galunisertib (a Small Molecule Inhibitor of the Kinase Domain of Type 1 TGF-B Receptor) in Patients With Newly Diagnosed, Persistent or Recurrent Carcinosarcoma of the Uterus or Ovary
Phase of Trial: Phase I
Latest Information Update: 28 Sep 2017
At a glance
- Drugs Galunisertib (Primary) ; Carboplatin; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Uterine cancer
- Focus Therapeutic Use
- 25 Sep 2017 Status changed from not yet recruiting to recruiting.
- 07 Jul 2017 Planned initiation date changed from 30 Jun 2017 to 31 Jul 2017.
- 04 Jul 2017 New trial record